4). The AUC of the model that combined IL28B genotype and serum IP-10

(AUC 0.80) clearly outperformed the models based on the individual variables, including the model based on IL28B genotype alone (AUC 0.70). The addition of race and baseline viral load further improved the model, although the added gain was modest (AUC up to 0.85). This is the first study to combine the highly useful IL28B genotype with baseline IP-10 levels to demonstrate an independent and additive model for predicting SVR with PEG-IFN and ribavirin treatment. We demonstrated that low pretreatment Quizartinib in vivo serum IP-10 is associated with SVR in both CA and AA HCV genotype 1 patients from the VIRAHEP-C cohort. Using pretreatment serum IP-10 (above or below 600 pg/mL) as a predictive biomarker for treatment response in our cohort revealed a positive predictive value of 69% and a negative predictive value of 67%. These results are in line with other studies, confirming that pretreatment IP-10 is lower in patients who subsequently achieve SVR on therapy compared with nonresponder patients.15-20 The prognostic use of baseline IP-10 levels has also been confirmed in other difficult-to-treat populations, such as patients coinfected with HCV and human immunodeficiency virus15 and patients

with an elevated viral load and body mass index.18 The current study greatly extends the potential clinical use DAPT of IP-10 and refines the predictive value of IL28B gene polymorphisms. Based on five genome-wide association studies, single nucleotide polymorphisms predictive of both spontaneous and treatment-induced viral clearance in HCV genotype 1 have been identified near the IL28B gene.21, 24-27 Carriage of a C allele at the IL28B gene polymorphism (rs12979860)

is favorably associated with treatment response to PEG-IFN and ribavirin in both AA and CA patients.21 This was confirmed in our VIRAHEP-C check details cohort with SVR rates of 87% with CC, 50% with CT, and 39% with TT genotypes. Most striking, stratification by high or low baseline IP-10 (above or below 600 pg/mL) further improved the predictability of SVR among the genotype groups, especially in IL28B T allele carriers. Multivariate analysis confirmed that IL28B genotype and baseline IP-10 levels are independent and additive predictors of HCV treatment response. Likewise, in a predictive model of SVR, serum IP-10 can be used as a dynamic variable, which complements the static IL-28B genotype and further individualizes treatment response. The polymorphisms on chromosome 19 associated with HCV treatment response are in the region that encodes the IFN-λ genes (IL28A, IL28B, and IL29). The IL28B gene encodes IFN-λ3, which has a unique signaling receptor as well as a common downstream signaling system with type I IFNs.22, 23 The role of IFN-λ in control of multiple viral infections, including HCV, is currently under study.